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counted for 1.5 percent of the average cost of admission
($125 of $7974 total cost, 90% CI: $96–$224). Relative
to no prophylaxis, the incremental cost per VTE avoided
using enoxaparin was $1330  468.
CONCLUSIONS: Acutely ill medical patients are at high
risk of VTE with treatment costs ranging from approxi-
mately $2500 (outpatient) to $25,000 (inpatient). Chronic
care for post-thrombotic syndrome, experienced in 20%-
56% of deep vein thrombosis patients further increases
the cost burden. This analysis demonstrates that VTE
prophylaxis with enoxaparin, in acutely ill medical pa-
tients has both economic and clinical benefits.
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OBJECTIVES: Cerebrovascular accidents (CVA) affect
120,000 French people each year. The aim of the study
was to calculate the cost of managing these patients.
METHODS: A Markov model was used in which four
clinical conditions were distinguished: first ischaemic
event; first cerebral haemorrhage; recurrent ischaemic
event; recurrent haemorrhagic event. Three lines of man-
agement were identified after hospitalisation: rehabilita-
tion, home, and geriatric institutions. Three levels of in-
capacity were identified using the Barthel index. Patients’
pathways in the health-care system were identified from
the only French register (Dijon) related to this disease
The specific death rates were calculated at 3, 6, 9 and 12
months. The severity of sequelae was assessed using the
Barthel index at 3 and 12 months. The clinical benefit
was measured as survival without loss of independence
(Barthel 95-100). All of the cost calculations were made
from the perspective of the community. Expenditures
were discounted at a rate of 5%.
RESULTS: The time horizon used for the model was five
years. 54.7% of the patients died during this time. The
average incapacity times after hospitalization over the
five years were: 70% slight incapacity (Barthel 95-100);
15% moderate incapacity (Barthel 60-90), and 15% se-
vere incapacity (Barthel 0-55). The total cost of manag-
ing the 120,000 cases of cerebrovascular accidents was
approximately 17 billion francs over the five years fol-
lowing the event. Twenty four percent (4.1 billion FF) of
this cost was related to short-term hospitalizations, 16.5%
(2.8 billion FF) to admissions to re-education or rehabili-
tation institutions, 33% (5.6 billion FF) to institutional
management, and 26.5% (4.5 billion FF) to looking after
patients at home. A sensitivity analysis was conducted
specially frequency with which health-care professionals
visited the patients at home.
CONCLUSION: This method allows for the calculation of
long-term costs of new cases of cerebrovascular accident.
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OBJECTIVE: The aim of the study was to assess the
costs and cost distribution of hypertension in Poland and
to compare the societal burden of hypertension on an in-
ternational basis.
METHODS: The time horizon of the analysis was 12
months and a retrospective approach was applied. The direct
medical costs of pharmacological treatment, doctor consulta-
tions, laboratory and diagnostic tests and hospitalizations
were identified and calculated. Indirect costs due to lost pro-
ductivity were also included in the analysis. All of the cost
components were collected with the aid of a cost assessment
formula, which was included in the epidemiological protocol.
RESULTS: Based on data collected from 9286 patients, the
average cost per hypertensive patient per year was calcu-
lated at 1570 PLN. The total burden of hypertension in
Poland may reach as much as 14 billion PLN per year. The
distribution of total costs is as follows: pharmacological
treatment, 10.2%; doctor consultations, 30.8%; labora-
tory and diagnostic tests, 11.4%; hospitalizations, 21.0%,
and productivity loss, 26.6%. An international compari-
son demonstrated that expenditures incurred as a result of
the pharmacological treatment of hypertension in Poland
were much lower than in other countries (i.e. Sweden:
53.3%, USA: 20.7%). Theoretically the total burden of
hypertension on society per year amounts to 31 USD in
Sweden, 82 USD in the United States and 88 USD in Po-
land using exchange rates available on January 21, 2000.
CONCLUSION: The results of the analysis demonstrate
that hypertension constitutes an important economic
burden for the Polish population. The cost of pharmaco-
logical treatment represents the lowest percentage of the
total cost of hypertension and the smallest portion of di-
rect medical costs. The conclusion is that an optimal allo-
cation of expenditure for pharmacological treatment may
contribute to a significant reduction of the total cost of
hypertension following the example of other European
countries such as Sweden as well as the United States.
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OBJECTIVE: To study costs and effectiveness of com-
mon practice treatment for critical limb ischemia at Mos-
cow hospitals.
METHODS: Data was obtained from 105 medical charts
from six Moscow hospitals. Inclusion criteria were: criti-
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cal limb ischemia (Fountain stage III-IV) at admission;
length of stay no less than 2 weeks; conservative manage-
ment before surgery for one week at least. Patient charac-
teristics, length of stay (LOS) and discharge status were
assessed. Amputation was considered as treatment fail-
ure. Direct medical costs for pharmacotherapy, diagnos-
tic and treatment services were calculated.
RESULTS: Mean age of patients was 63,8  11,46 years;
84,8% were men. Duration of critical limb ischemia before
admission varied from two weeks to 14 months. Mean LOS
was 31  14 days. From 1 to 41 drugs (12,9  8,6) were
prescribed to patients during hospitalization. Most fre-
quently used drugs were pentoxifyllin and rheopolygluci-
num (77,1% and 58% of patients). Amputation was per-
formed on 41,9% patients, and angioplasty on 32,4%.
Median cost of treatment in the study group was 35 462,70
rub (1 222.9$). The median cost for treating patients with
amputation was 41 698,41 rub (1437.9$), and the median
cost for patients with angioplasty was 43 802,3 rub
(1510.4$). Median cost for patients without surgical inter-
vention was significantly lower - 14 423,4 rub (497.4$).
CONCLUSION: Common practice treatment for critical
limb ischemia in Moscow hospitals requires amputation
in 41,9 % of cases. Costs for management patients with
amputation do not differ from costs for management of
patients requiring angioplasty when all direct costs are
taken into account.
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During the development of hypertension, a progressive in-
crease in left ventricular mass (LVM) occurs. This hyper-
trophy is a predictor of the incidence of cardiovascular
disease and mortality. The great majority of anti-hyperten-
sive drugs lead to a reduction of LVM, thus improving the
prognosis. It is not known, however, which of these drugs
is the most cost-effective in terms of reduction of LVM.
OBJECTIVE: To investigate the cost of reducing LVM
by 1 gram with various agents during the treatment of
hypertension.
METHODS: Out of 28 trials published between 1984
and 1995, only 17 were included (528 patients, 21 drugs
from main anti-hypertensive classes including ACE inhib-
itors, or drug combinations) because they were of 12
months duration. The cost of drugs used (at Polish prices)
for the treatment period was divided by the change in
LVM in grams during that period.
RESULTS: The most cost-effective drugs in terms of
LVM reduction (USD/gram of muscle) were: atenolol
0,11; prazosin 0,34; hydralazine 0,44. Combinations of
anti-hypertensives were highly cost-effective: rezerpine 
hydrochlorothiazide 0,11; atenolol  indapamide 0,92.
CONCLUSION: These results may serve as a guide in deci-
sion-making for the choice of treatment and reimbursement.
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OBJECTIVES: A Chest Pain Unit (CPU) with a diagnos-
tic algorithm employing troponin T (TnT) assay was im-
plemented in a public hospital in Hong Kong in February
2000. The aim of this study was to compare the cost-
effectiveness in risk stratification of chest pain (CP) pa-
tients before and after the implementation of a CPU from
the perspective of a public-health organization.
METHODS: Medical records of patients with CP pre-
sented to the Accident & Emergency (A&E) department in
November 1999 (pre-CPU) and November 2000 (post-
CPU) were reviewed. Patients with non-diagnostic CP
were recruited. Resource utilization for CP diagnosis was
retrieved from medical records. The clinical outcome (30-
day post-discharge re-admission or death secondary to car-
diac causes) was obtained from follow-up phone interview
and hospital records for patients discharged home from
A&E or CPU. Cost-effectiveness ratios (CERs) for the two
study periods and incremental CER were calculated.
RESULTS: There were 689 and 836 patients presented to
A&E with CP in November 1999 and November 2000,
respectively. The percentage of patients discharged from
A&E was higher in the pre-CPU group (64.7% vs.
50.5%, p  .001). A total of 529 patients in the pre-CPU
group and 581 patients in the pre-CPU group with non-
diagnostic CP were recruited. The cost of differential di-
agnosis for CP per patient was HK$2,934 (1USD  7.8
HKD) in the pre-CPU group and HK$3,641 in the post-
CPU group. The 30-day, post-discharge, cardiac-event
rate was 8.4% in pre-CPU group vs. 5.6% in post-CPU
group (p  .172). The CERs were HK$3,203 (pre-CPU)
and HK$3,857 (post-CPU) per patient per 30-day, car-
diac-event-free period. The incremental CER for the post-
CPU group was HK$25,245 per additional patient per
30-day, cardiac-event-free period.
CONCLUSION: Based on the data obtained, the imple-
mentation of a CPU appears to be able to reduce the 30-
day cardiac event rate with an incremental CER of
HK$25,245.
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